Chemistry:IBMX
From HandWiki
| |||
| Names | |||
|---|---|---|---|
| IUPAC name
1-Methyl-3-(2-methylpropyl)-7H-purine-2,6-dione
| |||
| Other names
3-Isobutyl-1-methylxanthine
| |||
| Identifiers | |||
3D model (JSmol)
|
|||
| ChEBI | |||
| ChEMBL | |||
| ChemSpider | |||
| DrugBank | |||
| KEGG | |||
PubChem CID
|
|||
| UNII | |||
| |||
| |||
| Properties | |||
| C10H14N4O2 | |||
| Molar mass | 222.3 g/mol | ||
| Appearance | White solid | ||
| Melting point | 199 to 201 °C (390 to 394 °F; 472 to 474 K) | ||
| Solubility | Soluble in ethanol, DMSO, and methanol | ||
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |||
 verify (what is   ?)
| |||
| Infobox references | |||
Tracking categories (test):
IBMX (3-isobutyl-1-methylxanthine), like other methylated xanthine derivatives, is both a:
- competitive non-selective phosphodiesterase inhibitor[1] which raises intracellular cAMP, activates PKA, inhibits TNFα[2][3] and leukotriene[4] synthesis, and reduces inflammation and innate immunity,[4] and
- nonselective adenosine receptor antagonist.[5]
As a phosphodiesterase inhibitor, IBMX has IC50 = 2–50 μM[6] and does not inhibit PDE8 or PDE9.[7]
References
- ↑ Essayan, DM (November 2001). "Cyclic Nucleotide Phosphodiesterases". The Journal of Allergy and Clinical Immunology 108 (5): 671–80. doi:10.1067/mai.2001.119555. PMID 11692087.
- ↑ Deree, J; Martins, JO; Melbostad, H; Loomis, WH; Coimbra, R (June 2008). "Insights into the Regulation of TNF-α Production in Human Mononuclear Cells: The Effects of Non-Specific Phosphodiesterase Inhibition". Clinics (Sao Paulo) 63 (3): 321–8. doi:10.1590/S1807-59322008000300006. PMID 18568240.
- ↑ Marques, LJ; Zheng, L; Poulakis, N; Guzman, J; Costabel, U (February 1999). "Pentoxifylline Inhibits TNF-α Production from Human Alveolar Macrophages". American Journal of Respiratory and Critical Care Medicine 159 (2): 508–11. doi:10.1164/ajrccm.159.2.9804085. PMID 9927365. http://www.atsjournals.org/doi/full/10.1164/ajrccm.159.2.9804085#readcube-epdf.
- ↑ 4.0 4.1 Peters-Golden, M; Canetti, C; Mancuso, P; Coffey, MJ (15 January 2005). "Leukotrienes: Underappreciated Mediators of Innate Immune Responses". Journal of Immunology 174 (2): 589–94. doi:10.4049/jimmunol.174.2.589. PMID 15634873. http://www.jimmunol.org/content/174/2/589.full.pdf.
- ↑ Daly, JW; Jacobson, KA; Ukena, D (1987). "Adenosine Receptors: Development of Selective Agonists and Antagonists". Progress in Clinical and Biological Research 230: 41–63. PMID 3588607.
- ↑ Beavo, JA; Rogers, NL; Crofford, OB; Hardman, JG; Sutherland, EW; Newman, EV (November 1970). "Effects of Xanthine Derivatives on Lipolysis and on Adenosine 3',5'-Monophosphate Phosphodiesterase Activity". Molecular Pharmacology 6 (6): 597–603. PMID 4322367.
- ↑ Soderling, SH; Beavo, JA (April 2000). "Regulation of cAMP and cGMP Signaling: New Phosphodiesterases and New Functions". Current Opinion in Cell Biology 12 (2): 174–9. doi:10.1016/s0955-0674(99)00073-3. PMID 10712916.
 |  |
